A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Phase 2 Completed 101 enrolled AbbVie Bristol-Myers Squibb · collab

Non-randomizedParallel-groupOpen-labelTreatment

The purpose of this study is to evaluate the combination of elotuzumab, lenalidomide, and dexamethasone in subjects with relapsed multiple myeloma.

Evaluation	Drug	Modality	Dose	Route
Subject	Elotuzumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Elotuzumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Elotuzumab	Monoclonal antibody	20 mg/kg	Intravenous
Background	Dexamethasone	Small molecule	40 mg	Oral
Background	Lenalidomide	Other / unclassified	25 mg	Oral